Pharmaron Beijing Co., Ltd. (HKG:3759)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
19.00
+0.81 (4.45%)
At close: Mar 6, 2026
20.25%
Market Cap 52.53B
Revenue (ttm) 14.80B
Net Income (ttm) 1.65B
Shares Out n/a
EPS (ttm) 0.94
PE Ratio 31.78
Forward PE 21.79
Dividend 0.22 (1.16%)
Ex-Dividend Date Jul 4, 2025
Volume 4,061,140
Average Volume 4,570,628
Open 18.02
Previous Close 18.19
Day's Range 18.02 - 19.11
52-Week Range 10.46 - 30.12
Beta 1.14
RSI 42.64
Earnings Date Mar 31, 2026

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotide... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 21,370
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3759
Full Company Profile

Financial Performance

In 2024, Pharmaron Beijing's revenue was 12.28 billion, an increase of 6.39% compared to the previous year's 11.54 billion. Earnings were 1.79 billion, an increase of 12.01%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.